Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
Cited by 76
Related Papers
Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer
|Cancer Medicine|2019|318
Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients
|Clinical and Translational Medicine|2020|31
The protective role of miR-223 in sepsis-induced mortality
|Scientific Reports|2020|29
Artesunate protects against a mouse model of cerulein and lipopolysaccharide‑induced acute pancreatitis by inhibiting TLR4‑dependent autophagy
|International Journal of Molecular Medicine|2024|11
Cloning and Transcriptional Activity of the Mouse Omi/HtrA2 Gene Promoter
|International Journal of Molecular Sciences|2016|8